ObjectiveThis review aims to systematically evaluate the effect of decalcified freeze-dried bone allograft (DFDBA) combined with rich platelet derivatives on the treatment of human periodontal intrabony defects.MethodsA search in PubMed, Web of Science, Embase, Cochrane Library, CNKI, and other electronic databases was conducted to iden-tify randomized controlled trials (RCT) of the use of DFDBA combined with rich platelet derivatives in the treatment of human periodontal intrabony defects, performed before May 2016. The quality of the RCTs was assessed.RevMan 5.3 software was applied for Meta-analysis.ResultsA total of nine RCTs were included. A total of 194 patients and 303 defects were involved. Short-term (6 months) and long-term (12 to 18 months) groups were included. Meta-analysis results revealed that DFDBA combined with rich platelet derivatives was superior to DFDBA or rich platelet derivatives alone for probing depth reduction in the short-term [MD=0.75 mm, 95% confidence intervals (CI) (0.31 mm, 1.20 mm),P=0.001 0] and long-term groups [MD=0.87 mm, 95%CI (0.02 mm, 1.72 mm),P=0.04], clinical attachment level gain in the short-term [MD=0.65 mm, 95%CI (0.08 mm, 1.22 mm),P=0.03] and long-term groups [MD=1.31 mm, 95%CI (0.60 mm, 2.01 mm),P<0 .000 3], gingival recession reduction in the long-term group [md="-0.58" mm, 95%ci (-0.78 mm, -0.38mm),P<0 .000 01], bone fill gain in the short-term [md="0.52" mm, 95%ci (0.03 mm, 1.00 mm),P=0.04] and long-term groups [MD=1.26 mm, 95%CI (0.65 mm, 1.86 mm),P<0 .000 1].ConclusionDFDBA combined with platelet rich derivatives is probably effective in the treatment of human periodontal intrabony defects. It is probably superior to DFDBA or platelet rich derivatives alone. Consi-dering the limitation of the included studies, high-quality and large-sample RCTs are required to evaluate the effect.
